News
Click here for news in Danish.
December 23, 2022 | Company Announcements
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus VaccineDecember 22, 2022 | Press Releases
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older AdultsDecember 08, 2022 | Managers' Transactions
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such December 08, 2022 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 24, 2022 | Managers' Transactions
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 23, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 17, 2022 | Company Announcements
Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox VaccinesNovember 09, 2022 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2022October 17, 2022 | Company Announcements
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial October 14, 2022 | Press Releases
Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox VaccineOctober 03, 2022 | Press Releases
Bavarian Nordic Enters Agreement with Country in Latin America on the Supply of Monkeypox Vaccines September 20, 2022 | Company Announcements
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic September 20, 2022 | Company Announcements
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to CanadaSeptember 07, 2022 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseSeptember 07, 2022 | Company Announcements
Bavarian Nordic Enters Additional Monkeypox Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) September 02, 2022 | Company Announcements
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine CandidateAugust 24, 2022 | Press Releases
Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the CaribbeanAugust 24, 2022 | Company Announcements
Bavarian Nordic Announces First Half 2022 ResultsAugust 23, 2022 | Company Announcements
Elizabeth McKee Anderson Resigns from the Board of Directors of Bavarian Nordic August 18, 2022 | Press Releases
Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines August 03, 2022 | Company Announcements
Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023 July 27, 2022 | Press Releases
Bavarian Nordic Receives U.S. and EU Approvals of its Fill and Finish Vaccine Manufacturing Facility July 25, 2022 | Press Releases
Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include MonkeypoxJuly 22, 2022 | Company Announcements
Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox July 19, 2022 | Company Announcements
Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023